Azacitidine (AZA) Days 1 - 5

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Liping Dou

Conditions

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONAcute Myeloid Leukaemia (AML)LeukemiaMDS (Myelodysplastic Syndrome)RelapseT-cell Acute Lymphoblastic Leukemia

Phase 1

A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT

Active, not recruitingNCT07779031

Liping DouAcute Myeloid Leukaemia (AML), MDS (Myelodysplastic Syndrome)

Start: 2025-05-01End: 2028-05-01Target: 58Updated: 2026-08-21

Phase 2

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

CompletedNCT02269280

M.D. Anderson Cancer CenterLeukemia

Start: 2014-10-13End: 2024-07-25Updated: 2025-08-07

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

RecruitingNCT06686108

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineT-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse

Start: 2024-10-30End: 2028-10-30Target: 59Updated: 2025-05-07

Related Papers

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Blood2025-11-03

Early Intervention with Hypomethylating Agents in Transfusion-Independent Patients with Myelodysplastic Syndrome

Blood2019-11-131 citations